LifeMD announces a cash dividend of $0.5546875 for preferred stock, payable October 15, 2025.
Quiver AI Summary
LifeMD, Inc. has announced the authorization of a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, with payment scheduled for October 15, 2025, to those on record by October 3, 2025. The company, a leader in virtual primary care, provides telemedicine and healthcare services across over 200 conditions, supported by a proprietary digital care platform and affiliated medical and pharmacy services. The press release includes a cautionary note about forward-looking statements related to the company’s financial outlook and performance, emphasizing the uncertainty and risks involved in predictions about future results and conditions.
Potential Positives
- LifeMD, Inc. has authorized a cash dividend of $0.5546875 per share to holders of its Series A Cumulative Perpetual Preferred Stock, demonstrating financial strength and a commitment to returning value to shareholders.
- The dividend is scheduled to be paid on October 15, 2025, indicating the company's ability to meet its financial obligations and providing a clear timeline for investors.
Potential Negatives
- The announcement of a cash dividend, while positive for preferred shareholders, may raise concerns among common shareholders regarding the allocation of resources and the ability to reinvest in the company's growth.
- The inclusion of extensive forward-looking statements highlights the uncertainty in LifeMD's financial outlook, which could lead to skepticism among investors about future performance.
- The press release does not provide current operational metrics or specific achievements, which may raise questions about the company's recent performance and long-term viability.
FAQ
What is the cash dividend announced by LifeMD?
LifeMD has authorized a cash dividend of $0.5546875 per share for its preferred stockholders.
When will the LifeMD dividend be paid?
The dividend will be paid on October 15, 2025, to holders of record as of October 3, 2025.
Who is eligible for the LifeMD preferred dividend?
Eligible recipients are holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock.
What services does LifeMD provide?
LifeMD provides virtual primary care, telemedicine, laboratory and pharmacy services for over 200 conditions.
Where can I find more information about LifeMD?
More information can be found on LifeMD's official website at LifeMD.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFMD Insider Trading Activity
$LFMD insiders have traded $LFMD stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $LFMD stock by insiders over the last 6 months:
- MARC DAVID BENATHEN (Chief Financial Officer) has made 0 purchases and 2 sales selling 125,000 shares for an estimated $1,682,440.
- JUSTIN SCHREIBER (Chairman and CEO) has made 0 purchases and 6 sales selling 150,000 shares for an estimated $1,473,065.
- STEFAN GALLUPPI (Chief Innovation Officer) sold 85,000 shares for an estimated $1,052,657
- NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760
- ERIC HAROLD YECIES (Chief Legal Officer & GC) sold 15,000 shares for an estimated $183,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LFMD Hedge Fund Activity
We have seen 91 institutional investors add shares of $LFMD stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NUVEEN, LLC added 882,362 shares (+310.7%) to their portfolio in Q2 2025, for an estimated $12,017,770
- UBS GROUP AG added 859,444 shares (+1103.4%) to their portfolio in Q2 2025, for an estimated $11,705,627
- MORGAN STANLEY added 847,262 shares (+113.6%) to their portfolio in Q2 2025, for an estimated $11,539,708
- D. E. SHAW & CO., INC. added 643,978 shares (+111.8%) to their portfolio in Q2 2025, for an estimated $8,770,980
- RENAISSANCE TECHNOLOGIES LLC added 600,100 shares (+123.5%) to their portfolio in Q2 2025, for an estimated $8,173,361
- CITADEL ADVISORS LLC removed 485,182 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,608,178
- TWO SIGMA INVESTMENTS, LP added 420,127 shares (+1382.0%) to their portfolio in Q2 2025, for an estimated $5,722,129
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LFMD Analyst Ratings
Wall Street analysts have issued reports on $LFMD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2025
- Lake Street issued a "Buy" rating on 08/06/2025
To track analyst ratings and price targets for $LFMD, check out Quiver Quantitative's $LFMD forecast page.
$LFMD Price Targets
Multiple analysts have issued price targets for $LFMD recently. We have seen 4 analysts offer price targets for $LFMD in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $13.0 on 08/07/2025
- Scott Schoenhaus from Keybanc set a target price of $12.0 on 08/06/2025
- Brooks O'Neil from Lake Street set a target price of $14.0 on 08/06/2025
Full Release
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
The preferred dividend will be paid on October 15, 2025, to holders of record at the close of business on October 3, 2025.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit
LifeMD.com
.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
[email protected]
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]